|
Arecor Therapeutics PLC on Wednesday said it has partnered with an unnamed biopharmaceutical company to develop a novel formulation of peptide therapy. The Cambridgeshire, England-based biopharmaceutical company said the clinical-stage firm that develops peptide therapies would fund Arecor’s development activities, with the option to then license the rights to the new formulation, to further develop and commercialise the product. Arecor said it will develop the therapy using its proprietary technology platform, Arestat. ‘Peptides are an increasingly important class of therapeutics to treat a wide range of chronic conditions,’ said Chief Executive Officer Sarah Howell. ‘Arecor’s significant expertise in developing novel formulations of therapeutic peptides to address unmet patient needs in this large and growing market. This collaboration further validates our leadership in this field.’ The global peptide therapeutics market is forecast to reach more than $100 billion by 2034, at a compound annual growth rate of 10.8%, Arecor also noted. Arecor continues to progress its development of oral versions of its peptide therapies, including its initial oral glucagon-like peptide-1 receptor against programme, which would provide patients an alternative to the usual injectable treatments. Shares in Arecor Therapeutics were up 3.6% at 52.30 pence each in London on Wednesday afternoon. The stock remains down 61% over the past year. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
